Pipeline Briefing
HomeCompaniesInvestigationsThe Drug Pipeline
LEAD INVESTIGATION

Why is AbbVie considered a controversial drugmaker?

A House investigation concluded AbbVie exploited the patent system to extend Humira's US monopoly four years longer than in Europe, raised its price 27 times, and engaged in shadow pricing with its closest competitor.

Nate Mercer·September 29, 2026
Investigations·September 27

What is OxyContin and why is it at the centre of the opioid crisis?

An extended-release oxycodone approved in 1995 — promoted as a long-term pain solution for common chronic conditions — whose aggressive marketing is linked to about 900,000 deaths since 1999 and more than $30 billion in Purdue revenues.

Evan Park
The Drug Pipeline·September 24

What is the generic drug price-fixing scandal?

Federal criminal cases and state civil suits allege that manufacturers agreed to divide customers and coordinate price increases on 100+ common medicines — Teva is the lead defendant — with some increases exceeding 1,000%.

Nate Mercer
Companies·September 22

Why is Biogen considered controversial?

Aduhelm — approved over the FDA's own advisers' objections, priced at $56,000, subjected to an 18-month congressional investigation and eventually discontinued — is the defining episode in a company already carrying a $900 million kickback settlement.

Julia Reyes

Recent

CompaniesWhy is AbbVie considered a controversial drugmaker?September 29InvestigationsWhat is OxyContin and why is it at the centre of the opioid crisis?September 27The Drug PipelineWhat is the generic drug price-fixing scandal?September 24CompaniesWhy is Biogen considered controversial?September 22InvestigationsWhat was Aduhelm and why was its approval such a big deal?September 19The Drug PipelineWhy is the adalimumab market so important?September 17
Pipeline Briefing

Deals, regulators, and what they don't tell you.